Dr. Nowakowski on Evolving Treatment Paradigm of MCL

Grzegorz S. Nowakowski, MD
Published: Thursday, Apr 20, 2017



Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

MCL is an area where a lot of new agents are being developed, Nowakowski explains. Moreover, what is interesting is that there is a paradigm shift from chemotherapy-based combinations to targeted therapy-based regimens in the relapsed setting. These include ibrutinib (Imbruvica) plus rituximab (Rituxan) and lenalidomide (Revlimid) and rituximab. Venetoclax (Venclexta) is another agent being explored in these regimens.

Over time, some of these more novel regimens are likely to replace chemotherapy in the relapsed setting, he adds..


Grzegorz Nowakowski, MD, assistant professor of medicine, Mayo Clinic, discusses the evolving treatment paradigm of mantle cell lymphoma (MCL).

MCL is an area where a lot of new agents are being developed, Nowakowski explains. Moreover, what is interesting is that there is a paradigm shift from chemotherapy-based combinations to targeted therapy-based regimens in the relapsed setting. These include ibrutinib (Imbruvica) plus rituximab (Rituxan) and lenalidomide (Revlimid) and rituximab. Venetoclax (Venclexta) is another agent being explored in these regimens.

Over time, some of these more novel regimens are likely to replace chemotherapy in the relapsed setting, he adds..



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x